Articles
November 5, 2019
A Truly Special Place for Science
Recently, our company was named Science Magazine’s Top Employer for 2019 – a significant achievement in the scientific community and a true milestone...
Read More ›
October 25, 2019
Alnylam Named #1 Biopharma Employer by Science Magazine
Alnylam has been named the #1 science employer in biopharma for 2019 by Science Magazine and Science Careers. This is our first appearance on the list.
Read More ›
October 1, 2019
The Importance of Ensuring Quality in a New Class of Medicines
In Product Quality, we have a truly big picture view of the medicines we’re making to ensure they are compliant with good manufacturing practices and...
Read More ›
October 1, 2019
Building for Our Future
Why would a company without a commercially approved medicine decide to build a significant manufacturing facility? Why not continue to rely on contract...
Read More ›
September 17, 2019
+MyFamily Program with 23andMe Aims to Increase Awareness of TTR-Related Hereditary Amyloi ...
hATTR amyloidosis is a potentially devastating and life-threatening condition that may affect families, generation after generation.
Read More ›
September 14, 2019
"Beyond the Visible" Art Exhibit Raises Awareness of Acute Hepatic Porphyria in Italy
This past weekend, "Beyond the Visible," a first of its kind exhibition of original works of art created by a group of graphic design and art students...
Read More ›
September 9, 2019
Alnylam's Patient Access Philosophy - Our Progress
Nearly two years ago – before we launched our first product – we made a commitment to strive toward broad patient access to our medicines. In our view...
Read More ›
August 8, 2019
Call for Entries: Deadline Extended - Submit Your Original Art Depicting Life with hATTR A ...
“The Art of Living with hATTR Amyloidosis” is a new initiative inviting members of the hereditary ATTR (hATTR) amyloidosis community – including patients...
Read More ›
June 24, 2019
Alnylam Honored by NORD with a Rare Impact Award
Alnylam Honored by NORD with a Rare Impact Award for the development and approval of ONPATTRO (patisiran).
Read More ›
